Flavio C.
- Country
- Portugal
- Department
- Serviço de Reumatologia
Research Overview
- Long-Term Safety, Tolerability, and Efficacy of Zasocitinib in Adults With Active Psoriatic Arthritis: A Phase 3 Extension Study
- A Randomized, Double‑Blind, Placebo‑Controlled Trial of Oral Nerandomilast (BI 1015550) in Patients with Systemic Sclerosis
- Efficacy and Safety Evaluation of Zasocitinib (TAK-279) Versus Apremilast and Placebo in Biologic-Naïve Adults with Active Psoriatic Arthritis
Data & Insights
Has run more than one trial at 85 of 179 partner sites.
Specializations
Autoimmune Rheumatic Diseases
The investigator’s work emphasizes the pathophysiology and therapeutic strategies for rheumatoid arthritis and related inflammatory joint disorders.
- Upadacitinib in rheumatoid arthritis
- Biologic agents for psoriatic arthritis
- Targeted synthetic DMARDs in juvenile idiopathic arthritis
Clinical trials address disease activity, structural progression, and safety across diverse patient populations.
Systemic Lupus Erythematosus and Lupus Nephritis
Research targets immune modulation in systemic lupus erythematosus and its renal manifestations.
- Cenerimod for active SLE
- Iptacopan in lupus nephritis
- Deucravacitinib for moderate-to-severe SLE
Focus is on organ‑specific outcomes and biomarkers of therapeutic response.
Vasculitis and Related Syndromes
Investigations cover small to medium vessel inflammation such as Behçet’s syndrome and Sjögren’s syndrome.
- Therapeutic approaches for antiphospholipid syndrome
- Management of immune thrombocytopenia
- Treatment strategies for immune‑mediated necrotizing myopathy
Emphasis is placed on interdisciplinary care and long‑term organ protection.
Cardiovascular and Metabolic Comorbidities in Rheumatology
The investigator integrates cardiovascular risk reduction with rheumatic disease management, including atherosclerotic cardiovascular disease and metabolic disorders.
- Inclisiran for major adverse cardiovascular events
- ARNI and SGLT2i initiation in heart failure with reduced ejection fraction
- Olezarsen for hypertriglyceridemia in patients with inflammatory disease
Trials evaluate the combined impact on cardiac outcomes and inflammatory burden.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.